Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2014 Jul 31;32(35):4399-403. doi: 10.1016/j.vaccine.2014.06.064. Epub 2014 Jun 24.

Achieving high uptake of human papillomavirus vaccine in Cameroon: lessons learned in overcoming challenges.

Author information

1
University of Massachusetts Medical School, Worcester, MA, United States. Electronic address: javier.ogembo@umassmed.edu.
2
Cameroon Baptist Convention Health Services, Bamenda, Cameroon.
3
Pathfinder International, Watertown, MA, United States.
4
Northeastern University, Boston, MA, United States.

Abstract

BACKGROUND:

Cameroon has the highest age-standardized incidence rate of cervical cancer (30/100,000 women) in Central Africa. In 2010-2011, the Cameroon Baptist Convention Health Services (CBCHS) received donated human papillomavirus (HPV) vaccine, Gardasil, from Merck & Co. Inc. through Axios Healthcare Development to immunize 6400 girls aged 9-13 years. The aim was to inform the Cameroon Ministry of Health (MOH) of the acceptability, feasibility, and optimal delivery strategies for HPV vaccine.

METHODS AND FINDINGS:

Following approval by the MOH, CBCHS nurses educated girls, parents, and communities about HPV, cervical cancer, and HPV vaccine through multimedia coverage, brochures, posters, and presentations. Because educators were initially reluctant to allow immunization in schools, due to fear of adverse events, the nurses performed 40.7% of vaccinations in the clinics, 34.5% in community venues, and only 24.7% in schools. When no adverse events were reported, more schools and communities permitted HPV vaccine immunization on their premises. To recover administrative costs, CBCHS charged a fee of US$8 per 3-dose series only to those who were able to pay. Despite the fee, 84.6% of the 6,851 girls who received the first dose received all three doses.

CONCLUSIONS AND LESSONS LEARNED:

With adequate education of all stakeholders, HPV vaccination is acceptable and feasible in Cameroon. Following this demonstration project, in 2014 the Global Access to Vaccines and Immunization (GAVI) Alliance awarded the Cameroon MOH HPV vaccine at a price of US$4.50 per dose to immunize sixth grade girls and girls aged 10 years who are not in school in two districts of Cameroon.

KEYWORDS:

Cameroon; Cervical cancer; Human papillomavirus; Vaccine

PMID:
24968154
DOI:
10.1016/j.vaccine.2014.06.064
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center